INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$128.79
-0.42 (-0.33%)
Open$129.00
Previous Close$129.21
Day High$134.06
Day Low$124.75
52W High$155.29
52W Low$10.84
Volume—
Avg Volume514.4K
Market Cap1.82B
P/E Ratio—
EPS$-6.24
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
-85.9% upside
Current
$128.79
$128.79
Target
$18.13
$18.13
$12.39
$18.13 avg
$27.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.18M | 1.41M | 384.43M |
| Net Income | -127,719,806 | -136,777,517 | -115,444,062 |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% |
| EBITDA | -121,216,172 | -137,024,468 | -155,644,267 |
| Free Cash Flow | — | — | -85,235,104 |
| Rev Growth | -16.0% | -16.0% | -5.8% |
| Debt/Equity | 12.58 | 12.58 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |